This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Zadnik V, Primic Žakelj M. SLORA: Slovenija in rak. Epidemiologija in register raka. Ljubljana: Epidemiologija in register raka. Onkološki inštitut Ljubljana. [cited 2019 April 15]. Available at: http://www.slora.siZadnikVPrimicŽakelj MLjubljanaEpidemiologija in register raka. Onkološki inštitut Ljubljana[cited 2019 April 15]. Available athttp://www.slora.siSearch in Google Scholar
Curigliano G, Burstein HJ, Winer E, Gnant M, Dubsky P, Loibl S, et al. Deescalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700-12. doi: 10.1093/ annonc/mdx308CuriglianoGBursteinHJWinerEGnantMDubskyPLoiblSet alDeescalating and escalating treatments for early-stage breast cancer: the St2017Ann Oncol 2017;2817001210.1093/ annonc/mdx308Open DOISearch in Google Scholar
Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-44. doi: 10.1016/S0140-6736(11)61625-5PetoRDaviesCGodwinJGrayRPanHCClarkeMet alComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials20123794324410.1016/S0140-6736(11)61625-5327372322152853Open DOISearch in Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717. doi: 10.1016/S0140-6736(05)66544-0Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials2005365168771710.1016/S0140-6736(05)66544-015894097Open DOISearch in Google Scholar
Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS. Clinical relevance of the 21-gene Recurrence Score((R)) assay in treatment decisions for patients with node-positive breast cancer in the genomic era. NPJ Breast Cancer 2018; 4: 27. doi: 10.1038/s41523-018-0082-6MamounasEPRussellCALauATurnerMPAlbainKSClinical relevance of the 21-gene Recurrence Score((R)) assay in treatment decisions for patients with node-positive breast cancer in the genomic era201842710.1038/s41523-018-0082-6610229630155517Open DOISearch in Google Scholar
Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75: 284-98. doi: 10.1016/j.ejca.2017.01.017DuffyMJHarbeckNNapMMolinaRNicoliniASenkusEet alClinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)2017752849810.1016/j.ejca.2017.01.01728259011Open DOISearch in Google Scholar
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, et al. Use of bio-markers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2017; 35: 2838-47. doi: 10.1200/JCO.2017.74.0472KropIIsmailaNAndreFBastRCBarlowWCollyarDEet alUse of bio-markers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update20173528384710.1200/JCO.2017.74.0472584618828692382Open DOISearch in Google Scholar
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5: v8-30. doi: 10.1093/ annonc/mdv298SenkusEKyriakidesSOhnoSPenault-LlorcaFPoortmansPRutgersEet alPrimary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up201526Suppl5v83010.1093/ annonc/mdv298Open DOISearch in Google Scholar
National Comprehensive Cancer Network. NCCN Guidelines Version 1.2019 Breast Cancer.[cited 2019 June 6] Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf[cited 2019 June 6] Available athttps://www.nccn.org/professionals/physician_gls/pdf/breast.pdfSearch in Google Scholar
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65. doi: 10.1016/S1470-2045(09)70314-6AlbainKSBarlowWEShakSHortobagyiGNLivingstonRBYehITet alPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial201011556510.1016/S1470-2045(09)70314-6305823920005174Open DOISearch in Google Scholar
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26. doi: 10.1056/NEJMoa041588PaikSShakSTangGKimCBakerJCroninMet alA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer200435128172610.1056/NEJMoa04158815591335Open DOISearch in Google Scholar
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34. doi: 10.1200/ JCO.2005.04.7985PaikSTangGShakSKimCBakerJKimWet alGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer20062437263410.1200/ JCO.2005.04.7985Open DOISearch in Google Scholar
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379: 111-21. doi: 10.1056/NEJMoa1804710SparanoJAGrayRJMakowerDFPritchardKIAlbainKSHayesDFet alAdjuvant chemotherapy guided by a 21-gene expression assay in breast cancer20183791112110.1056/NEJMoa1804710617265829860917Open DOISearch in Google Scholar
Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-34. doi: 10.1200/JCO.2009.24.4798DowsettMCuzickJWaleCForbesJMallonEASalterJet alPrediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study20102818293410.1200/JCO.2009.24.479820212256Open DOISearch in Google Scholar
Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52. doi: 10.1093/jnci/djp335SimonRMPaikSHayesDFUse of archived specimens in evaluation of prognostic and predictive biomarkers200910114465210.1093/jnci/djp335278224619815849Open DOISearch in Google Scholar
Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016; 34: 2341-9. doi: 10.1200/JCO.2015.63.5383GluzONitzUAChristgenMKatesREShakSClemensMet alWest German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment2016342341910.1200/JCO.2015.63.538326926676Open DOISearch in Google Scholar
Roberts MC, Miller DP, Shak S, Petkov VI. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat 2017; 163: 303-10. doi: 10.1007/s10549-017-4162-3RobertsMCMillerDPShakSPetkovVIBreast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database20171633031010.1007/s10549-017-4162-328243896Open DOISearch in Google Scholar
Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, et al. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. NPJ Breast Cancer 2017; 3: 32. doi: 10.1038/s41523-017-0033-7StemmerSMSteinerMRizelSGeffenDBNisenbaumBPeretzTet alClinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry201733210.1038/s41523-017-0033-7559131428900632Open DOISearch in Google Scholar
ClinicalTrials.gov Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. [cited 2019 July 11] Available at: https://clinicaltrials.gov/ct2/show/NCT01272037ClinicalTrials.gov[cited 2019 July 11] Available athttps://clinicaltrials.gov/ct2/show/NCT01272037Search in Google Scholar
van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6. doi: 10.1038/415530avan‘t Veer LJDaiHvande Vijver MJHeYDHartAAMaoMet alGene expression profiling predicts clinical outcome of breast cancer2002415530610.1038/415530a11823860Open DOISearch in Google Scholar
Tian S, Roepman P, Van’t Veer LJ, Bernards R, de Snoo F, Glas AM. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 2010; 5: 129-38. doi: 10.4137/BMI. S6184TianSRoepmanPVan’tVeer LJBernardsRdeSnoo FGlasAMBiological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer201051293810.4137/BMI. S6184Open DOISearch in Google Scholar
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. doi: 10.1056/NEJMoa021967vande Vijver MJHeYDvan’tVeer LJDaiHHartAAVoskuilDWet alA gene-expression signature as a predictor of survival in breast cancer20023471999200910.1056/NEJMoa02196712490681Open DOISearch in Google Scholar
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-92. doi: 10.1093/ jnci/djj329BuyseMLoiSvan’t VeerLVialeGDelorenziMGlasAMet alValidation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer20069811839210.1093/ jnci/djj329Open DOISearch in Google Scholar
Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, van den Akker J, et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn 2014; 16: 190-7. doi: 10.1016/j.jmoldx.2013.10.008SapinoARoepmanPLinnSCSnelMHDelahayeLJvan denAkker Jet alMammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue201416190710.1016/j.jmoldx.2013.10.00824378251Open DOISearch in Google Scholar
Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, van Tinteren H, Wesseling J, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133: 929-36. doi: 10.1002/ijc.28082DrukkerCABueno-de-MesquitaJMRetelVPvan HartenWHvan TinterenHWesselingJet alA prospective evaluation of a breast cancer prognosis signature in the observational RASTER study20131339293610.1002/ijc.28082373462523371464Open DOISearch in Google Scholar
Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23: 2716-25. doi: 10.1200/JCO.2005.06.178OlivottoIABajdikCDRavdinPMSpeersCHColdmanAJNorrisBDet alPopulation-based validation of the prognostic model ADJUVANT! for early breast cancer20052327162510.1200/JCO.2005.06.17815837986Open DOISearch in Google Scholar
Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010; 21: 717-22. doi: 10.1093/annonc/mdp388MookSSchmidtMKWeigeltBKreikeBEekhoutIvan deVijver MJet alThe 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age2010217172210.1093/annonc/mdp38819825882Open DOISearch in Google Scholar
Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3: 540-51. doi: 10.1038/ ncponc0591BogaertsJCardosoFBuyseMBragaSLoiSHarrisonJAet alGene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial200635405110.1038/ ncponc0591Open DOISearch in Google Scholar
Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26: 729-35. doi: 10.1200/JCO.2007.14.3222CardosoFVan’tVeer LRutgersELoiSMookSPiccart-GebhartMJClinical application of the 70-gene profile: the MINDACT trial2008267293510.1200/JCO.2007.14.322218258980Open DOISearch in Google Scholar
Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375: 717-29. doi: 10.1056/NEJMoa1602253CardosoFvan’t VeerLJBogaertsJSlaetsLVialeGDelalogeSet al70-Gene signature as an aid to treatment decisions in early-stage breast cancer20163757172910.1056/NEJMoa160225327557300Open DOISearch in Google Scholar
Esserman LJ, Yau C, Thompson CK, van ‘t Veer LJ, Borowsky AD, Hoadley KA, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol 2017; 3: 1503-10. doi: 10.1001/jamaoncol.2017.1261EssermanLJYauCThompsonCKvan‘t Veer LJBorowskyADHoadleyKAet alUse of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades2017315031010.1001/jamaoncol.2017.1261571019728662222Open DOISearch in Google Scholar
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013; 109: 2959-64. doi: 10.1038/bjc.2013.671DubskyPBraseJCJakeszRRudasMSingerCFGreilRet alThe EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients201310929596410.1038/bjc.2013.671385994924157828Open DOISearch in Google Scholar
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-20. doi: 10.1158/1078-0432.CCR-11-0926FilipitsMRudasMJakeszRDubskyPFitzalFSingerCFet alA new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors20111760122010.1158/1078-0432.CCR-11-092621807638Open DOISearch in Google Scholar
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7. doi: 10.1200/JCO.2008.18.1370ParkerJSMullinsMCheangMCLeungSVoducDVickeryTet alSupervised risk predictor of breast cancer based on intrinsic subtypes2009271160710.1200/JCO.2008.18.1370266782019204204Open DOISearch in Google Scholar
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25: 339-45. doi: 10.1093/annonc/mdt494GnantMFilipitsMGreilRStoegerHRudasMBago-HorvathZet alPredicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone2014253394510.1093/annonc/mdt49424347518Open DOISearch in Google Scholar
Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011; 104: 1762-9. doi: 10.1038/bjc.2011.145JerevallPLMaXJLiHSalungaRKestyNCErlanderMGet alPrognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial20111041762910.1038/bjc.2011.145311115921559019Open DOISearch in Google Scholar
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013; 105: 1036-42. doi: 10.1093/jnci/djt146SgroiDCCarneyEZarrellaESteffelLBinnsSNFinkelsteinDMet alPrediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker201310510364210.1093/jnci/djt146388813823812955Open DOISearch in Google Scholar
Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-90. doi: 10.1200/JCO.2012.46.1558DowsettMSestakILopez-KnowlesESidhuKDunbierAKCowensJWet alComparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy20133127839010.1200/JCO.2012.46.155823816962Open DOISearch in Google Scholar
Harbeck N, Thomssen C. A new look at node-negative breast cancer. Oncologist 2011; 16 Suppl 1: 51-60. doi: 10.1634/theoncologist.2011-S1-51HarbeckNThomssenCA new look at node-negative breast cancer201116Suppl1516010.1634/theoncologist.2011-S1-5121278441Open DOISearch in Google Scholar
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009; 116: 295-302. doi: 10.1007/s10549-008-0130-2MookSSchmidtMKVialeGPruneriGEekhoutIFlooreAet alThe 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study200911629530210.1007/s10549-008-0130-218661261Open DOISearch in Google Scholar
Chang MC, Souter LH, Kamel-Reid S, Rutherford M, Bedard P, Trudeau M, et al. Clinical utility of multigene profiling assays in early-stage breast cancer. Curr Oncol 2017; 24: e403-e22. doi: 10.3747/co.24.3595ChangMCSouterLHKamel-ReidSRutherfordMBedardPTrudeauMet alClinical utility of multigene profiling assays in early-stage breast cancer201724e403e2210.3747/co.24.3595565916529089811Open DOISearch in Google Scholar
Clark GM. Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. Mol Oncol 2008; 1: 406-12. doi: 10.1016/j.molonc.2007.12.001ClarkGMPrognostic factors versus predictive factors: Examples from a clinical trial of erlotinib200814061210.1016/j.molonc.2007.12.001554383219383314Open DOISearch in Google Scholar
Ballman KV. Biomarker: Predictive or Prognostic? J Clin Oncol 2015; 33: 3968-71. doi: 10.1200/JCO.2015.63.3651BallmanKVBiomarker: Predictive or Prognostic?20153339687110.1200/JCO.2015.63.365126392104Open DOISearch in Google Scholar
Bhutiani N, Egger ME, Ajkay N, Scoggins CR, Martin RC, 2nd, McMasters KM. Multigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making. J Am Coll Surg 2018; 226: 406-12 e1. doi: 10.1016/j.jamcollsurg.2017.12.043BhutianiNEggerMEAjkayNScogginsCRMartinRC2ndMcMastersKMMultigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making201822640612e110.1016/j.jamcollsurg.2017.12.04329366844Open DOISearch in Google Scholar
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer 2016; 2: 16017. doi: 10.1038/npjbcancer.2016.17PetkovVIMillerDPHowladerNGlinerNHoweWSchusslerNet alBreast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study201621601710.1038/npjbcancer.2016.17551532928721379Open DOISearch in Google Scholar
Su KW, Hall J, Soulos PR, Abu-Khalaf MM, Evans SB, Mougalian SS, et al. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. J Geriatr Oncol 2016; 7: 15-23. doi: 10.1016/j.jgo.2015.11.002SuKWHallJSoulosPRAbu-KhalafMMEvansSBMougalianSSet alAssociation of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-201120167152310.1016/j.jgo.2015.11.00226704661Open DOISearch in Google Scholar
Potosky AL, O’Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, et al. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer 2015; 121: 4062-70. doi: 10.1002/cncr.29621PotoskyALO’NeillSCIsaacsCTsaiHTChaoCLiuCet alPopulation-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years201512140627010.1002/cncr.29621463504226291519Open DOISearch in Google Scholar
Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012; 30: 2218-26. doi: 10.1200/JCO.2011.38.5740HassettMJSilverSMHughesMEBlayneyDWEdgeSBHermanJGet alAdoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer20123022182610.1200/JCO.2011.38.5740339771822585699Open DOISearch in Google Scholar
Blok EJ, Bastiaannet E, van den Hout WB, Liefers GJ, Smit V, Kroep JR, et al. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. Cancer Treat Rev 2018; 62: 74-90. doi: 10.1016/j.ctrv.2017.10.012BlokEJBastiaannetEvan denHout WBLiefersGJSmitVKroepJRet alSystematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe201862749010.1016/j.ctrv.2017.10.01229175678Open DOISearch in Google Scholar
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018; 4: 545-53. doi: 10.1001/jamaoncol.2017.5524SestakIBuusRCuzickJDubskyPKronenwettRDenkertCet alComparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial201845455310.1001/jamaoncol.2017.5524588522229450494Open DOISearch in Google Scholar
Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J Natl Cancer Inst 2016; 108: pii: djw050. doi: 10. 1093/jnci/djw050BartlettJMBayaniJMarshallADunnJACampbellACunninghamCet alComparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others2016108pii: djw05010. 1093/jnci/djw050Open DOISearch in Google Scholar